In contrast, whereas GLS demonstrated anti-oncogenic roles in bladder, kidney, and lung cancer, GLS2 acted as a tumor suppressor in brain, kidney, pancreatic, and skin cancer. This evidence concerns the gene GLS2 and neoplasm.